[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sikora et al., 2021 - Google Patents

Cellular senescence in brain aging

Sikora et al., 2021

View HTML
Document ID
3656029931573678950
Author
Sikora E
Bielak-Zmijewska A
Dudkowska M
Krzystyniak A
Mosieniak G
Wesierska M
Wlodarczyk J
Publication year
Publication venue
Frontiers in aging neuroscience

External Links

Snippet

Aging of the brain can manifest itself as a memory and cognitive decline, which has been shown to frequently coincide with changes in the structural plasticity of dendritic spines. Decreased number and maturity of spines in aged animals and humans, together with …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Sikora et al. Cellular senescence in brain aging
Hemonnot et al. Microglia in Alzheimer disease: well-known targets and new opportunities
Xuan et al. Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of Alzheimer’s disease
Cenini et al. Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Zhang et al. Generation of a novel mouse model of Parkinson’s disease via targeted knockdown of glutamate transporter GLT-1 in the substantia nigra
El Bekay et al. Enhanced markers of oxidative stress, altered antioxidants and NADPH‐oxidase activation in brains from Fragile X mental retardation 1‐deficient mice, a pathological model for Fragile X syndrome
US10240156B2 (en) Modulation of synaptic maintenance
Cui et al. KLF 4 Knockdown Attenuates TBI‐Induced Neuronal Damage through p53 and JAK‐STAT 3 Signaling
Min et al. Neuregulin-1 prevents amyloid β-induced impairment of long-term potentiation in hippocampal slices via ErbB4
Ezerskiy et al. Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Sangineto et al. Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease
Huang et al. Protective effects of wogonin against Alzheimer’s disease by inhibition of amyloidogenic pathway
Hong et al. Celastrol targeting Nedd4 reduces Nrf2-mediated oxidative stress in astrocytes after ischemic stroke
Qi et al. The consequences of reducing expression of the α7 nicotinic receptor by RNA interference and of stimulating its activity with an α7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease
Cheng et al. Triggering receptor expressed on myeloid cells-2 (TREM2) interacts with colony-stimulating factor 1 receptor (CSF1R) but is not necessary for CSF1/CSF1R-mediated microglial survival
Gao et al. Platelet regulates neuroinflammation and restores blood–brain barrier integrity in a mouse model of traumatic brain injury
Akhter et al. The pro-apoptotic protein Bmf co-operates with Bim and Puma in neuron death induced by β-amyloid or NGF deprivation
Marwarha et al. Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-ΚB)–a Friend, a Foe, or a Bystander-in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
Liu et al. Spinal Glia Division Contributes to Conditioning Lesion–Induced Axon Regeneration Into the Injured Spinal Cord: Potential Role of Cyclic AMP–Induced Tissue Inhibitor of Metalloproteinase-1
Xie et al. OTUB1 attenuates neuronal apoptosis after intracerebral hemorrhage
Song et al. Hyperphosphorylated tau inflicts intracellular stress responses that are mitigated by apomorphine
Otgongerel et al. Induction of ICAM1 in brain vessels is implicated in an early AD pathogenesis by modulating neprilysin
Pisciottani et al. Neuronal models of TDP-43 proteinopathy display reduced axonal translation, increased oxidative stress, and defective exocytosis
Zhou et al. Nrdp1 increases neuron apoptosis via downregulation of Bruce following intracerebral haemorrhage
Wu et al. Lithium chloride exerts anti-inflammatory and neuroprotective effects by inhibiting microglial activation in LPS-induced retinal injury